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AIMS
Pragmatic randomized clinical trials (pRCTs) collect data that have the potential to improve medical care signiﬁcantly. However,
these trials may be undermined by the requirement to obtain written informed consent, which can decrease accrual and increase
selection bias. Recent data suggest that the majority of the US public endorses written consent for low-risk pRCTs. The present
study was designed to assess whether this view is speciﬁc to the US.
METHODS
The study took the form of a cross-sectional, probability-based survey, with a 2 × 2 factorial design, assessing support for written
informed consent vs. verbal consent or general notiﬁcation for two low-risk pRCTs in hypertension, one comparing two drugs
with similar risk/beneﬁt proﬁles and the other comparing the same drug being taken in the morning or at night. The primary
outcome measures were respondents’ personal preference and hypothetical recommendation to a research ethics committee
regarding the use of written informed consent vs. the alternatives.
RESULTS
A total of 2008 adults sampled from a probability-based online panel responded to the web-based survey conducted in May 2016
(response rate: 61%). Overall, 77% of respondents endorsed written consent. In both scenarios, the alternative of general
notiﬁcation received signiﬁcantly more support (28.7–37.1%) than the alternative of verbal consent (12.7–14.0%) (P = 0.001).
Forty per cent of respondents preferred and/or recommended general notiﬁcation rather than written consent.
CONCLUSIONS
The results suggested that, rather than attempting to waive written consent, current pRCTs should focus on developing ways to
implement written consent that provide sufﬁcient information without undermining recruitment or increasing selection bias. The
ﬁnding that around 40% of respondents endorsed general notiﬁcation over written consent raises the possibility that, with
educational efforts, the majority of Spaniards might accept general notiﬁcation for low-risk pRCTs.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• To facilitate recruitment and reduce selection bias, commentators have proposed the use of brief verbal consent or general
notiﬁcation in place of in-depth written consent for low-risk pragmatic randomized controlled trials (pRCTs).
• However, a survey from the US found that the majority of the public endorses written consent for low-risk pRCTs. It is
unknown whether this support for written consent is speciﬁc to the US or applies in the EU as well.
WHAT THIS STUDY ADDS
• The present study found that the majority of the Spanish population endorses written consent for low-risk pRCTs.
• This ﬁnding suggests that support for written consent is not restricted to the US, and pRCTs in the EU should focus on
developing approaches to written consent that provide sufﬁcient information without undermining recruitment or
increasing selection bias.
• The ﬁnding that around 40% of respondents endorse general notiﬁcation over written consent suggests that, with
educational efforts, it might be feasible in the future to conduct low-risk pRCTs in Spain, and perhaps in other EU
countries, using general notiﬁcation rather than study-speciﬁc written consent.
Introduction
Pragmatic randomized clinical trials (pRCTs) that assess
standard-of-care interventions are important for improving
clinical care. In particular, these studies can provide
important data to help national health systems determine
which interventions provide the best healthcare beneﬁt for
the money [1] Yet, EU and US regulations require written
consent for almost all clinical trials, no matter what level of
risk they pose. This requirement, which leads to complex
and long (15 pages or more) consent forms, which take a long
time to read and are difﬁcult to understand [2], has the
potential to undermine the value of pRCTs. In response to
these concerns, some commentators have argued that written
informed consent is not ethically necessary for pRCTs [3–6]
that pose no or onlyminimal incremental risk compared with
standard clinical care [7]
While these theoretical arguments are valuable, it is
important to assess what the public thinks of conducting
low-risk pRCTs without written consent. A study in the US
found that the majority of respondents (70–82%) were
willing to waive written consent for pRCTs, but only when
it would make a study ‘too difﬁcult to conduct’ [8]. In
addition, Nayak et al. [9] found that the majority of US
respondents (63%) endorse written consent for low-risk
pRCTs, while 37% endorse the alternative of verbal consent
or general notiﬁcation [9]. Recognizing that views on
informed consent can vary by culture [10] we replicated
the Nayak et al. [9] survey in Spain, to assess whether
majority support for written consent for low-risk pRCTs is
speciﬁc to the US.
Methods
Survey characteristics and administration, and
ethics review
A nationally representative online survey of Spanish citizens
was conducted between 9 and 20 May 2016. The study
protocol was reviewed by the research ethics committee
(REC) of the Universidad Autónoma de Madrid (Madrid,
Spain), which granted approval on 14 March 2016 (Ref. #
CEI-70-1265).
The survey was administered to participants belonging to
the Netquest (GfK group) panel, Spain. This is a probability-
based online closed panel to which potential members
are invited to join, with the goal of ensuring that it is
representative of the non-institutionalized civilian Spanish
population [with the exception of the oldest (≥75 years) age
group]. Netquest comprises more than 198 000 adult
members and has the ISO 26362, speciﬁc for free-access
panels. Panellists receive nonsurvey-speciﬁc incentives
through a point-based reward programme; points can be
exchanged for more than 1200 different items.
The survey was developed as described elsewhere [9]. In
short, two pretesting sessions and two pilot surveys were
used to ensure comprehension of the US survey and obtain
open-ended feedback. The survey was then revised
following feedback from two anonymous peer reviewers
for Time-sharing Experiments for the Social Sciences [9].
The US version of the survey was translated into Spanish
and adapted to the Spanish health system environment.
The ﬁnal Spanish version was identical to the US version,
except for a few sentences in the introduction. We omitted
references to ‘The Learning Healthcare System’ [11] – a
concept unknown in Spain – and substituted a short
description of conducting research in the context of
providing healthcare (Supporting Information Data S1).
The composition of the REC (as opposed to that of the US
Institutional Review Board) was also adapted to the Spanish
regulation.
To assess comprehension of the Spanish version, we
conducted a test on 100 individuals and found that most of
them (80–100%) correctly answered seven true/false
questions regarding the survey, such as on the need to have
clinical trials approved by an REC and whether the patient’s
treatment could be changed during the trial (Supporting
Information Data S2).
The survey assessed respondents’ views on consent for
low-risk pRCTs. Key elements of the survey are shown in
Box 1. All respondents received a common introduction
regarding the possibility of conducting research in the
context of providing healthcare and the need for clinical
trials to be approved by a REC. It was also explained that
hypertension is a condition that affect millions of Spaniards
and that, without treatment, it can lead to serious health
complications. Immediately after the introduction,
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respondents were randomly assigned to receive one of two
pRCT scenarios.
pRCTscenarios (see Box 1)
Scenario 1. A pRCT comparing two widely used
antihypertensive drugs that have been approved by the
Spanish health authorities. Respondents were informed that
both drugs had a low-risk proﬁle and were effective
antihypertensive agents. The examples were based on
two commonly used diuretics, chlorthalidone and
hydrochlorothiazide. However, in the survey, they were
called CTD and TRT, to prevent response bias among
respondents who might be familiar with the drugs.
Scenario 2.A pRCT assessing a once-daily antihypertensive
drug taken in themorning vs. at night. Respondents were told
that prescribers usually do not inform patients when to take
these drugs.
Consent options (see Box 1)
Respondents in each pRCT scenario were randomized to a
choice between written informed consent vs. brief verbal
consent, or between written informed consent vs. general
notiﬁcation.
• Written consent: To allow comparison with Nayak et al.
[9], the Spanish version described the same eight
elements of consent as required in the US. However,
respondents were not told that the eight listed elements
were based on US regulations. All respondents were
informed that obtaining written informed consent
requires extra time and effort from both the physician
and patient, making it difﬁcult to integrate research
studies like the one described into routine healthcare
practice.
• Verbal consent: the survey informed respondents that, in
this case, the physician brieﬂy explains the main features
Box 1
Experimental design of the survey (Modiﬁed from Nayak et al[9]).
Research conducted at the time of
providing healthcare
Hospitals that integrate research as part of care provision
Patients informed that studies are conducted through letters, posters and brochures
All studies are reviewed and approved by a REC, which comprises researchers, clinicians, ethicists, patient
representatives and community members
High blood pressure Affects millions of persons in Spain
Can lead to stroke, heart attack and/or kidney disease if untreated
Pragmatic RCT scenario Scenario 1: Drug ‘CTD’ or ‘TRT’?
Two health authorities-approved medicines
Both effective in lowering high blood pressure;
similar adverse effects
Unknown which is more effective
Scenario 2: Dose timing, ‘morning’ or ‘night’?
Patients told to take medicine at same time each day
Unknown whether morning or night more effective
Trial proposal Random assignment to CTD or TRT
Patient’s medicine can be changed at any time by
patient or physician
Random assignment of whether told to take medicine
at morning or night
Patient’s medicine can be changed at any time by
patient or physician
Debate REC is debating the best way to get consent for this study
Consent options Written consent
vs.
verbal consent
Written consent
vs.
general notiﬁcation
Written consent
vs.
verbal consent
Written consent
vs.
general notiﬁcation
Written consent • Some members argue that patients should give study-speciﬁc written consent
• Consent form would include purpose, risks and beneﬁts, alternatives, method of maintaining privacy, and
contact information; participation would be voluntary
• Written consent would require extra time and effort
• In some cases, if written consent is required, studies may not be conducted
Alternative option General notiﬁcation
• Other members argue that because the risks are low, general notiﬁcation through posters, brochures and
letters is enough
• Eligible patients would be automatically enrolled without being informed
Verbal consent
• Other members argue that because the risks are low, verbal consent is enough
• Patient’s physician would brieﬂy explain the study
Shows the 2 × 2 factorial design and information presented to respondents. Half received a drug RCT scenario comparing two ﬁrst-line drugs; the
others received a dose-timing RCT scenario comparing morning vs. night dosing. Half of participants in each group chose between written consent
and general notiﬁcation; the rest chose between written consent and verbal consent. CTD, chlorthalidone; RCT, randomized, controlled trial; REC,
research ethics committee; TRT = hydrochlorothiazide.
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of the trial, that the drug will be randomly assigned and will
ask the patient if he/she would like to participate.
• General notification: respondents were told that all patients
are informed through letters, posters and brochures that
the hospital conducts randomized trials and that
eligible patients would be enrolled without study-speciﬁc
consent.
Survey administration
Panel members were randomly assigned to one of the two
scenarios (the drug pRCT or dose-timing pRCT) at the time
they were invited to participate in the survey. Respondents
were further randomly assigned to general notiﬁcation or
verbal consent as an alternative to written consent when
they reached that part of the survey (see Box 1). The
randomizationswere computer generated andwere concealed
from respondents. Simple probability-based assignment was
used for randomization, and neither stratiﬁcation nor an
imbalanced allocation scheme was used. To minimize
missing data, respondents received a prompt if the primary
outcome measures were left blank. Before starting the
analysis, we decided to exclude respondents who did not
answer the questions on both primary outcome measures.
Responses from all participants were recorded in the database
in an anonymized fashion; participants could not be
identiﬁed by study investigators.
Outcome and measurements
Respondents were informed that the two choice options (i.e.
written consent vs. general notiﬁcation; written consent vs.
verbal consent) were both supported by some members of
the REC and were asked to make a recommendation to the
REC. Respondents were also asked which of the two options
they preferred personally.
Respondents were asked to evaluate the trial by
indicating whether they agreed, using a seven-point scale
(1 = strongly disagree, 7 = strongly agree), with the
following three statements: (i) ‘It is valuable to study
whether one treatment option is more effective than the
other for treating high blood pressure’; (ii) ‘Patients who
participate in the randomized trial face greater risks than
patients who receive usual care’; and (iii) ‘Patients who
participate in the randomized trial are more likely to
improve (lower) their high blood pressure than patients
who receive usual care’.
Statistical analysis
It was estimated that a sample size of 500 respondents in
each group would provide 80% power to detect a 9%
absolute difference for all baseline levels of support,
assuming a two-sided α level of 0.05. To evaluate the
representativeness of the sample in each group and to ensure
the absence of statistically signiﬁcant differences between
groups, we compared the sample distribution of socio-
demographics, and diagnosis and control of hypertension
in the four groups with that of the general population in
Spain.
To replicate the study by Nayak et al. [9],
recommendations to the REC and personal preferences for
written consent or the alternative approach were
dichotomized. Logistic regression models were used to assess
whether the pRCT scenario and alternative
consent/notiﬁcation option were associated with
respondents’ recommendations and personal preferences.
The models included the main effects for the research
scenario (drug pRCT; dose-timing pRCT) and the alternative
option (general notiﬁcation; verbal consent), as well as the
interaction of the two factors. Conditional logistic regression
was used to assess the relationship between respondents’
recommendations to the REC and their personal preferences.
Ordered logistic regression was used to assess the effect of the
research scenario on respondents’ perceptions of the study’s
value, risk and beneﬁt. To evaluate the association between
respondents’ perceptions of the study’s risk and support for
the alternative option, the Pearson chi-square test of
independence corrected for bootstrap was used.
All analyses were conducted in IBM SPSS statistics, version
21 (Armonk, NY, US). According to ﬁnal sample distribution,
poststratiﬁcation weights were not used. Statistical
signiﬁcance was deﬁned as a P value less than 0.05, and all
tests were two sided.
Results
Sample characteristics
The survey was presented to 3298 panel members and started
by 2243, of which 45 dropped out before they were
randomized to one of the two pRCT scenarios. After
randomization, 179 were excluded for nonresponses to one
of the two alternative options (written consent vs. general
notiﬁcation or written consent vs. verbal consent). Finally,
11 individuals were excluded for not responding to both
primary outcomes (recommendation to the REC and personal
preference), yielding 2008 panellist completers (response
rate: 60.9%) (Figure 1).
The sample did not show statistically signiﬁcant
differences with the Spanish adult population in any of
the variables shown in Table 1, except for age. In Spain,
11.4% [12] of the adult population is ≥75 years of age,
whereas in the study sample only 1.9% of subjects fell
within this age group. For this reason, poststratiﬁcation
weights were not used. 27.5% (552/2008) of respondents
indicated that they had been diagnosed with hypertension
and 16.8% (338/2008) reported being treated with
prescription medications. This latter ﬁgure was similar to
the 15.6% of known hypertensive people in Spain who
receive treatment [13]. The characteristics of the four groups
are given in Table 1; they were similar across the four groups
and resembled those of the Spanish population in almost all
variables.
Recommendations to the REC and personal
preferences
Overall, 77.1% of respondents said that they would deﬁnitely
or probably recommend use of written consent to the REC
(Figure 2A). In the drug pRCT, 29.7% said that they would
recommend general notiﬁcation, whereas 14% would
recommend verbal consent. In the dose-timing pRCT,
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35.1% said that they would recommend general notiﬁcation,
whereas 12.7% would recommend verbal consent instead of
written consent.
Overall, 76.9% of respondents said that they would
deﬁnitely or probably prefer the use of written consent
(Figure 2B). In the drug pRCT, 28.7% preferred general
notiﬁcation, whereas 13.6% preferred verbal consent. In the
dose-timing pRCT, 37.1% preferred general notiﬁcation,
whereas 12.9% preferred verbal consent instead of written
consent. Figure 3 shows respondents’ recommendations to
the REC and their personal preferences.
Considering only the 1003 respondents who had to
choose between written consent and general notiﬁcation in
both scenarios (drug pRCT and the dose-timing pRCT),
39.8% preferred and/or recommended general notiﬁcation.
Similarly, among the 1005 respondents choosing between
written consent and verbal consent, 16.7% preferred and/or
recommended verbal consent.
Responses to the two items were consistent across groups,
with most (85.6–93.4%) having the same recommendation
and personal preference (Table 2). In both scenarios (drug
pRCT and dose-timing pRCT), consistency was statistically
signiﬁcantly greater (93.1% vs. 85.6%; P< 0.001) when verbal
consent was the alternative option rather than general
notiﬁcation. The percentage of respondents who preferred
the alternative option was not statistically signiﬁcantly
different in any of the four groups compared with the
percentage of respondents who said that they would
recommend the alternative option to the REC (Figure 3).
A logistic regression model was used to test the effect of
the experimental design of the survey on recommendations
for using the alternative option over written consent. As
mentioned above, the main effect was the alternative option
presented; in both scenarios, drug pRCT and dose-timing
pRCT, a statistically signiﬁcant higher percentage of
respondents preferred the alternative option of general
notiﬁcation compared with those who preferred verbal
consent (P = 0.001). Although recommendation of general
notiﬁcation was greater in the dose-timing pRCT (35.1%)
than in the drug pRCT (29.7%), this difference was not
statistically signiﬁcant (P = 0.078).
With respect to personal preferences, the effect of the
alternative option presented reached statistical signiﬁcance:
more respondents preferred general notiﬁcation than
preferred brief verbal consent (P = 0.001). In this case, a
statistically signiﬁcant effect of the interaction ‘alternative
option and pRCT scenario’was observed. A higher percentage
of respondents preferred general notiﬁcation in the dose-
timing pRCT than in the drug pRCT (37.1% vs 28.7%; P =
0.003).
Views of pragmatic RCTscenarios
A large majority of respondents agreed that it is valuable to
conduct the study, with no signiﬁcant differences between
the two scenarios: 87.8% in the drug pRCT and 88.7% in the
dose-timing pRCT (Table 3). Some 31% of respondents in
both scenarios believed that trial participants would face
greater risks thanpatients, and 43% in both scenarios believed
that they were more likely to beneﬁt (have a reduction in
their blood pressure) than those receiving usual care.
Relationship between risk perception and
recommendation to the REC
Overall, respondents who believed that study participants
face greater risks than patients receiving usual care were not
Figure 1
Study ﬂow diagram. pRCT, pragmatic randomized controlled trial
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Table 1
Characteristics of survey respondents
Overall
Drug pRCT, % Dose-timing pRCT, %
(n = 2008)
n (%)
General notiﬁcation
(n = 501)
Verbal consent
(n = 501)
General notiﬁcation
(n = 502)
Verbal consent
(n = 504)
Age (years)
18-24 244 (12.2) 12.2 12.2 12.2 12.1
25-34 349 (17.4) 17.4 17.4 17.3 17.5
35-44 452 (22.5) 22.6 22.4 22.5 22.6
45-54 411 (20.5) 20.4 20.6 20.5 20.4
55-64 302 (15.0) 15.2 15.4 13.9 15.7
65-74 211 (10.5) 10.2 10.0 11.8 10.1
≧75 39 (1.9) 2.2 2.2 1.8 1.6
Gender
Male 997 (49.7) 52.7 49.9 49.8 46.2
Female 1011 (50.3) 47.3 50.1 50.2 53.8
Geographical area
North 309 (15.4) 15.0 15.6 16.2 15.0
North-east 381 (19.0) 20.6 17.6 18.5 19.3
East 285 (14.2) 12.8 15.0 13.8 15.3
Central-West 526 (26.2) 27.0 26.3 27.3 24.3
South 361 (18.0) 16.9 17.9 17.8 18.9
Islands 146 (7.2) 7.8 7.6 6.4 7.4
Marital status
Never married 498 (224.8) 26.1 23.2 25.9 24.0
Married 974 (48.5) 45.3 51.5 51.2 46.0
Divorced 105 (5.2) 7.2 4.8 4.4 4.6
Separated 37 (1.8) 1.6 2.4 2.0 1.4
Widowed 45 (2.2) 2.2 2.4 1.6 2.8
Living with partner 316 (15.7) 15.2 15.2 13.5 19.0
No answer 33 (1.6) 2.4 0.6 1.4 2.2
Annual household income (€)
<12 600 276 (13.7) 14 12.8 11.6 16.7
12 600–25 000 609 (30.3) 28.8 30.3 32.6 29.6
25 001–38 000 308 (15.3) 14.2 15.4 16.3 15.5
38 001–50 000 164 (8.2) 8.8 7.4 8.8 7.7
>50 000 90 (4.4) 8.8 7.4 8.8 7.7
No income 89 (4.4) 4.8 4.6 4.2 4.2
No answer 472 (23.5) 24.4 24.2 22.3 23.2
Employment status
Employed 957 (47.7) 46.9 50.5 47.2 46.0
Unemployed or other 591 (29.4) 29.3 26.5 30.1 31.7
Retired 262 (13.0) 13.2 13.2 12.7 13.1
Student 198 (9.9) 10.3 9.8 10.0 9.1
(continues)
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more likely to recommend the alternative option to written
consent compared with those who were neutral or disagreed.
When general notiﬁcation was the alternative option, there
were no statistically signiﬁcant differences in any of the
scenarios. By contrast, and only in the dose-timing pRCT
scenario, respondents who believed that participants face
greater risks than patients receiving usual care were
signiﬁcantly less likely (P < 0.001) to recommend verbal
consent (6.6%) compared with respondents whowere neutral
(7.2%) or disagreed (21.5%) (Table 4).
Discussion
The main ﬁnding of the present study was that written
informed consent is endorsed by the majority (77%) of the
Spanish population for low-risk pRCTs. This result is similar
to that obtained in the US [9] and suggests that a preference
for written informed consent in this setting is not restricted
to the US. Hence, rather than attempting to waive the
requirement for written consent, pRCTs in the EU should
attempt to develop approaches to written consent that
Table 1
(Continued)
Overall
Drug pRCT, % Dose-timing pRCT, %
(n = 2008)
n (%)
General notiﬁcation
(n = 501)
Verbal consent
(n = 501)
General notiﬁcation
(n = 502)
Verbal consent
(n = 504)
Education
Primary school 394 (19.6) 19.4 20.2 19.5 19.4
Secondary education 508 (25.3) 26.7 21.2 26.7 26.6
High school 682 (34.0) 32.7 36.3 34.9 31.9
University degree and
postgraduate
424 (21.1) 21.2 22.4 18.9 22.0
Religious attendance
Regularly 241 (12.0) 11.4 13.2 11.2 12.3
Rarely 370 (18.4) 20.0 18.0 16.9 18.8
Never 1196 (59.6) 58.9 60.5 62.2 56.7
No answer 201 (10.0) 9.8 8.4 9.8 12.1
Ideology
1 Extreme left 73 (2.8) 2.6 3.4 3.4 1.8
2 405 (15.1) 15.4 18.2 13.3 13.7
3 501 (18.2) 19.6 16.6 17.7 18.8
4 Moderate 800 (31.1) 29.5 31.1 32.7 31.2
5 260 (9.8) 10.2 9.8 9.2 9.9
6 97 (3.8) 2.4 5.2 3.8 4.0
7 Extreme right 36 (1.4) 1.2 0.8 2.4 1.2
No answer 445 (17.8) 19.2 15.0 17.5 19.4
Diagnosed with hypertension
Yes 552 (27.5) 28.7 26.9 27.3 27.0
No 1382 (68.8) 67.9 68.7 68.7 70.0
I don’t know 61 (3.0) 2.8 4.0 3.2 2.2
No answer 13 (0.6) 0.6 0.4 0.8 0.8
Prescription treatment for
hypertension
Yes, currently 338 (61.2) 59.0 63.0 62.0 62.0
Yes, but not currently 58 (10.5) 15.3 5.9 11.7 7.4
No 154 (27.9) 25.7 31.1 25.5 30.3
No answer 2 (0.4) 0.7 0.4
pRCT, pragmatic randomized controlled trial
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provide sufﬁcient information without decreasing
recruitment or increasing selection bias.
In the US survey, the alternative of verbal consent
received more support than general notiﬁcation [9]. By
contrast, in the present survey, the alternative of general
notiﬁcation received signiﬁcantly more support (some 33%)
than verbal consent (some 13%) (P = 0.001). This raises the
possibility that, with additional educational efforts, the
majority of the public in Spain, and perhaps other EU
countries, might endorse general notiﬁcation. This is
important because the use of general notiﬁcation has the
potential to increase recruitment, reduce selection bias and
make it more feasible to conduct pRCTs in real-world settings.
There are some differences between the results obtained
in Spain and in the US. [9]. In particular, 72% and 88% of
Americans and Spaniards, respectively, believed that it is
valuable to conduct pRCTs; some 21% in the US and 31% in
Spain believed that participants in pRCTs face additional
risks. Finally, 18% in the US but 43% in Spain believed that
participation in pRCTs offers additional beneﬁts compared
with standard care. This may reﬂect the fact that many
respondents to the present survey did not understand that
participation in the pRCT poses no additional risks and does
not offer additional beneﬁts compared with usual care.
Greater experience with RCTs in the US compared with
Spain, and the fact that the percentage of university
graduates responding to the Spanish survey (21%) was lower
than in the US study (29%) may help to explain these
differences. Finally, in the present survey, signiﬁcantly more
respondents (P = 0.003) supported general notiﬁcation in
the dose-timing pRCT than in the drug pRCT, something that
was not observed in the US study. This result is consistent
Figure 2
Recommendations to the research ethics committee (A) and personal preferences (B) for written consent and the alternative option. CI,
conﬁdence interval; L, lower limit; U, Upper limit; RCT, randomized controlled trial
R. Dal-Ré et al.
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with the hypothesis that the dose-timing pRCT might have
be perceived among Spanish respondents as more innocuous
than the drug pRCT [9].
Strengths and weaknesses of the study
To the best of our knowledge, this was the ﬁrst study
conducted in any EU member state assessing the opinion of
Figure 3
Support for alternative options to written consent. CI, conﬁdence interval; L, lower limit; U, Upper limit; RCT, randomized controlled trial
Table 2
Cross-tabulation of respondents’ recommendation to the research ethics committee and personal preferences
Variable
Overall, %
(n = 2008)
Drug pRCT, % Dose-timing pRCT, %
General notiﬁcation
(n = 501)
Verbal consent
(n = 501)
General notiﬁcation
(n = 502)
Verbal consent
(n = 504)
Recommended written consent,
preferred written consent
71.8 63.7 82.6 56.8 83.9
Recommended written consent,
preferred alternative option
5.4 6.6 3.4 8.2 3.4
Recommended alternative option,
preferred written consent
5.2 7.6 3.8 6.2 3.2
Recommended alternative option,
preferred alternative option
17.7 22.2 10.2 28.9 9.5
pRCT, pragmatic randomized controlled trial
Table 3
Views of the public on statements about social value, risk and beneﬁt of the pragmatic randomized controlled trial (pRCT) scenario
Statement Scenario
Response, % P value
Disagree Neutral Agree
It is valuable to study whether one treatment option is more
effective than the other for treating high blood pressure
Drug pRCTa 4.5 7.7 87.8 0.586
Dose-timing pRCTb 4.7 6.7 88.7
Patients who participate in the randomized trial face greater
risks than patients who receive usual care
Drug pRCTa 34.7 31.6 33.6 0.053
Dose-timing pRCTb 37.8 32.7 29.5
Patients who participate in the randomized trial are more
likely to improve (lower) their high blood pressure than
patients who receive usual care.
Drug pRCTa 22.3 34.7 43.0 0.650
Dose-timing pRCTb 20.0 37.3 42.7
an = 1002
bn = 1006
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the public with regard to written informed consent for low-
risk pRCTs. However, it had several important limitations.
First, although the study was based on a probability-based
sample, it had a low percentage (1.9%) of ≥75-year-old
participants. Second, the response rate was 61%. It was not
possible to determine whether nonrespondents might have
differed from respondents. Third, framing effects and the
use of hypothetical scenarios might have inﬂuenced
respondents’ attitudes. In particular, the hypothetical
scenarios, involving pRCTs conducted in clinical settings,
were probably unfamiliar to many respondents. Lastly, the
study design did not allow us to assess directly which
alternative method (verbal consent or general notiﬁcation)
respondents would prefer or recommend.
Policy implications
The new EU regulation [14], to be implemented in 2018 [15],
distinguishes, for the ﬁrst time, low-intervention trials (phase
IV trials comparing medicines used in accordance with the
marketing authorization that pose minimal added risks) from
all other trials. Nonetheless, this regulation [14] requires in-
depth written informed consent for all trials, except for
cluster RCTs, which may enrol individuals who do not
explicitly opt out.
The present ﬁndings suggest that it will be crucial to
identify ways to implement written consent without
undermining low-risk pRCTs. For two low-risk pRCTs, UK
RECs have approved short consent forms that comply with
EU regulations; the 15-page consent forms for a typical
explanatory RCT have been reduced to a two-page
document [16, 17]. This approach – in which participants
receive the minimum amount of information needed to
make an informed decision – should be encouraged by EU
RECs, especially for point-of-care pRCTs conducted using
routinely collected data from electronic medical records
[16–18]. This short consent form could facilitate the
recruitment of participants to pRCTs and could help to
ensure that pRCTs are not terminated early owing to
insufﬁcient enrolment – a common feature within RCTs
[19, 20]. A further step to ease the consent process for
low-risk pRCTs, and hence facilitate recruitment even
further, would be to accept the simpliﬁed consent the new
EU regulation endorse for cluster RCTs. This is somewhat
aligned with a qualitative study conducted in the UK,
which found that the majority of 110 individuals supported
the use of simpliﬁed ‘opt-in’ models for low-risk, point-of-
care trials [21]. This change would require an amendment
of this regulation.
t the same time, it will be important to assess individuals
from several EU countries regarding general notiﬁcation vs.
in-depth written informed consent for low-risk pRCTs. As
information preferences may differ in response to hypothet-
ical scenarios, it will be important to survey patients [22]. If
there is sufﬁcient support, it might make sense to start
educational efforts to inform the public about the possibility
of conducting clinical trials at the same time as providing
clinical care. If successful, general notiﬁcation may increase
recruitment and decrease selection bias, and thus signiﬁ-
cantly improve the evidence available to inform healthcare
decision-making. However, this will involve a change in the
EU clinical trials regulation that will require a broad and in-
depth open discussion with interested stakeholders.
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Table 4
Percentage of respondents recommending the alternative option on the basis of perception of the study’s risk
Variable
Perception of study’s risk (95% CI), % a
All respondents
(95% CI)
P valueb
Disagreec Neutrald Agreee
Overall (n = 2008) 25.3 (22.3–28.5) 22.4 (19.2–26.0) 20.5 (17.6–23.7) 22.9 (21.2–24.7) 0.107
Drug pRCT
General notiﬁcation (n = 501) 31.3 (24.0–39.0) 27.7 (21.4–34.5) 30.3 (23.1–37.2) 29.7 (25.5–33.9) 0.763
Verbal consent (n = 501) 17.8 (12.7–23.6) 11.1 (6.6–16.2) 12.2 (7.6–17.6) 14.0 (11.3–17.2) 0.155
Dose-timing pRCT
General notiﬁcation (n = 502) 31.7 (24.5–38.7) 39.5 (32.8–47.6) 33.8 (26.3–41-1) 35.1 (30.5–39.5) 0.275
Verbal consent (n = 504) 21.5 (15.6–27.2) 7.2 (3.4–11.7) 6.6 (2.9–11.3) 12.7 (9.9–15.7) <0.001
CI, conﬁdence interval; pRCT, pragmatic randomized controlled trial
a‘Patients who participate in the randomized trial face greater risks than patients who receive usual care’
bPearson’s chi-square test of independence corrected by bootstrap
c1–3 on a seven-point scale
d4 on a seven-point scale
e5–7 on a seven-point scale
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